Literature DB >> 10888629

Use of inhibitors to evaluate coreceptor usage by simian and simian/human immunodeficiency viruses and human immunodeficiency virus type 2 in primary cells.

Y Zhang1, B Lou, R B Lal, A Gettie, P A Marx, J P Moore.   

Abstract

We have used coreceptor-targeted inhibitors to investigate which coreceptors are used by human immunodeficiency virus type 1 (HIV-1), simian immunodeficiency viruses (SIV), and human immunodeficiency virus type 2 (HIV-2) to enter peripheral blood mononuclear cells (PBMC). The inhibitors are TAK-779, which is specific for CCR5 and CCR2, aminooxypentane-RANTES, which blocks entry via CCR5 and CCR3, and AMD3100, which targets CXCR4. We found that for all the HIV-1 isolates and all but one of the HIV-2 isolates tested, the only relevant coreceptors were CCR5 and CXCR4. However, one HIV-2 isolate replicated in human PBMC even in the presence of TAK-779 and AMD3100, suggesting that it might use an undefined, alternative coreceptor that is expressed in the cells of some individuals. SIV(mac)239 and SIV(mac)251 (from macaques) were also able to use an alternative coreceptor to enter PBMC from some, but not all, human and macaque donors. The replication in human PBMC of SIV(rcm) (from a red-capped mangabey), a virus which uses CCR2 but not CCR5 for entry, was blocked by TAK-779, suggesting that CCR2 is indeed the paramount coreceptor for this virus in primary cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10888629      PMCID: PMC112207          DOI: 10.1128/jvi.74.15.6893-6910.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  117 in total

1.  Will multiple coreceptors need to be targeted by inhibitors of human immunodeficiency virus type 1 entry?

Authors:  Y J Zhang; J P Moore
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

2.  Use of coreceptors other than CCR5 by non-syncytium-inducing adult and pediatric isolates of human immunodeficiency virus type 1 is rare in vitro.

Authors:  Y J Zhang; T Dragic; Y Cao; L Kostrikis; D S Kwon; D R Littman; V N KewalRamani; J P Moore
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

3.  Evidence for differences in MT2 cell tropism according to genetic subtypes of HIV-1: syncytium-inducing variants seem rare among subtype C HIV-1 viruses.

Authors:  M Peeters; R Vincent; J L Perret; M Lasky; D Patrel; F Liegeois; V Courgnaud; R Seng; T Matton; S Molinier; E Delaporte
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1999-02-01

4.  Use of GPR1, GPR15, and STRL33 as coreceptors by diverse human immunodeficiency virus type 1 and simian immunodeficiency virus envelope proteins.

Authors:  A L Edinger; T L Hoffman; M Sharron; B Lee; B O'Dowd; R W Doms
Journal:  Virology       Date:  1998-09-30       Impact factor: 3.616

5.  V3 recombinants indicate a central role for CCR5 as a coreceptor in tissue infection by human immunodeficiency virus type 1.

Authors:  S Y Chan; R F Speck; C Power; S L Gaffen; B Chesebro; M A Goldsmith
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

6.  Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage.

Authors:  A Mörner; A Björndal; J Albert; V N Kewalramani; D R Littman; R Inoue; R Thorstensson; E M Fenyö; E Björling
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

7.  Enhancement of human immunodeficiency virus type 1 infection by the CC-chemokine RANTES is independent of the mechanism of virus-cell fusion.

Authors:  C J Gordon; M A Muesing; A E Proudfoot; C A Power; J P Moore; A Trkola
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

8.  The simian immunodeficiency virus mnd(GB-1) strain uses CXCR4, not CCR5, as coreceptor for entry in human cells.

Authors:  D Schols; E De Clercq
Journal:  J Gen Virol       Date:  1998-09       Impact factor: 3.891

9.  Adaptation to promiscuous usage of CC and CXC-chemokine coreceptors in vivo correlates with HIV-1 disease progression.

Authors:  L Xiao; D L Rudolph; S M Owen; T J Spira; R B Lal
Journal:  AIDS       Date:  1998-09-10       Impact factor: 4.177

10.  Natural infection of a homozygous delta24 CCR5 red-capped mangabey with an R2b-tropic simian immunodeficiency virus.

Authors:  Z Chen; D Kwon; Z Jin; S Monard; P Telfer; M S Jones; C Y Lu; R F Aguilar; D D Ho; P A Marx
Journal:  J Exp Med       Date:  1998-12-07       Impact factor: 14.307

View more
  74 in total

Review 1.  Receptors and entry cofactors for retroviruses include single and multiple transmembrane-spanning proteins as well as newly described glycophosphatidylinositol-anchored and secreted proteins.

Authors:  J Overbaugh; A D Miller; M V Eiden
Journal:  Microbiol Mol Biol Rev       Date:  2001-09       Impact factor: 11.056

2.  Early- and intermediate-stage variants of simian immunodeficiency virus replicate efficiently in cells lacking CCR5.

Authors:  Serene Forte; Mary-Elizabeth Harmon; Mario J Pineda; Julie Overbaugh
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

3.  The well-tempered SIV infection: Pathogenesis of SIV infection in natural hosts in the wild, with emphasis on virus transmission and early events post-infection that may contribute to protection from disease progression.

Authors:  Kevin Raehtz; Ivona Pandrea; Cristian Apetrei
Journal:  Infect Genet Evol       Date:  2016-07-06       Impact factor: 3.342

4.  In vitro phenotypic susceptibility of HIV-2 clinical isolates to CCR5 inhibitors.

Authors:  Benoit Visseaux; Charlotte Charpentier; Margarita Hurtado-Nedelec; Alexandre Storto; Romain Antoine; Gilles Peytavin; Florence Damond; Sophie Matheron; Françoise Brun-Vézinet; Diane Descamps
Journal:  Antimicrob Agents Chemother       Date:  2011-11-07       Impact factor: 5.191

5.  Stable reduction of CCR5 by RNAi through hematopoietic stem cell transplant in non-human primates.

Authors:  Dong Sung An; Robert E Donahue; Masakazu Kamata; Betty Poon; Mark Metzger; Si-Hua Mao; Aylin Bonifacino; Allen E Krouse; Jean-Luc Darlix; David Baltimore; F Xiao-Feng Qin; Irvin S Y Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-01       Impact factor: 11.205

6.  Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins.

Authors:  Denise L Kothe; Julie M Decker; Yingying Li; Zhiping Weng; Frederic Bibollet-Ruche; Kenneth P Zammit; Maria G Salazar; Yalu Chen; Jesus F Salazar-Gonzalez; Zina Moldoveanu; Jiri Mestecky; Feng Gao; Barton F Haynes; George M Shaw; Mark Muldoon; Bette T M Korber; Beatrice H Hahn
Journal:  Virology       Date:  2006-11-13       Impact factor: 3.616

7.  Tyrosine sulfation of CCR5 N-terminal peptide by tyrosylprotein sulfotransferases 1 and 2 follows a discrete pattern and temporal sequence.

Authors:  Christoph Seibert; Martine Cadene; Anthony Sanfiz; Brian T Chait; Thomas P Sakmar
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-08       Impact factor: 11.205

8.  Early control of highly pathogenic simian immunodeficiency virus/human immunodeficiency virus chimeric virus infections in rhesus monkeys usually results in long-lasting asymptomatic clinical outcomes.

Authors:  Tatsuhiko Igarashi; Yasuyuki Endo; Yoshiaki Nishimura; Charles Buckler; Reza Sadjadpour; Olivia K Donau; Marie-Jeanne Dumaurier; Ronald J Plishka; Alicia Buckler-White; Malcolm A Martin
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

9.  Nonpathogenic CCR2-tropic SIVrcm after serial passage and its effect on SIVmac infection of Indian rhesus macaques.

Authors:  Binhua Ling; Ronald S Veazey; Preston A Marx
Journal:  Virology       Date:  2008-07-26       Impact factor: 3.616

10.  Derivation and characterization of a simian immunodeficiency virus SIVmac239 variant with tropism for CXCR4.

Authors:  Gregory Q Del Prete; Beth Haggarty; George J Leslie; Andrea P O Jordan; Josephine Romano; Nathaniel Wang; Jianbin Wang; Michael C Holmes; David C Montefiori; James A Hoxie
Journal:  J Virol       Date:  2009-07-15       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.